Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- F-1 Registration statement (foreign)
- 3.1 Exhibit 3.1
- 10.1 Exhibit 10.1
- 10.2 Exhibit 10.2
- 10.3 Exhibit 10.3
- 10.4 Exhibit 10.4
- 10.5 Exhibit 10.5
- 10.6 Exhibit 10.6
- 10.7 Exhibit 10.7
- 10.8 Exhibit 10.8
- 10.9 Exhibit 10.9
- 10.10 Exhibit 10.10
- 10.11 Exhibit 10.11
- 10.12 Exhibit 10.12
- 10.13 Exhibit 10.13
- 10.14 Exhibit 10.14
- 10.15 Exhibit 10.15
- 10.16 Exhibit 10.16
- 21.1 Exhibit 21.1
- 23.1 Exhibit 23.1
- 99.1 Exhibit 99.1
Associated filings
- 18 May 20 424B4 Prospectus supplement with pricing info
- 15 May 20 EFFECT Notice of effectiveness
- 14 May 20 F-1/A Registration statement (foreign) (amended)
- 11 May 20 F-1/A Registration statement (foreign) (amended)
- 27 Apr 20 F-1/A Registration statement (foreign) (amended)
-
24 Apr 20 F-1 Registration statement (foreign)
ADCT similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the use in this Registration Statement on Form F-1 of ADC Therapeutics SA of our report dated March 2, 2020, except for the effects of the share consolidation discussed in Note 2 (v) to the consolidated financial statements, as to which the date is April 24, 2020 relating to the consolidated financial statements of ADC Therapeutics SA, which appears in this Registration Statement. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ PricewaterhouseCoopers SA
Lausanne, Switzerland
April 24, 2020
Lausanne, Switzerland
April 24, 2020